Paper41583504
POFUT2 Mediated Fucosylation of JUP Enhances VEGFA Expression to Promote Angiogenesis in Colorectal Cancer.
Zou Y and 4 others. Int J Med Sci, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. POFUT2 Mediated Fucosylation of JUP Enhances VEGFA Expression to Promote Angiogenesis in Colorectal Cancer. Papers, record 41583504. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41583504
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- POFUT2 Mediated Fucosylation of JUP Enhances VEGFA Expression to Promote Angiogenesis in Colorectal Cancer.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Neovascularization, Pathologic | Major topic |
| Fucosyltransferases | Major topic |
| Humans | |
| Human Umbilical Vein Endothelial Cells | |
| Gene Expression Regulation, Neoplastic | |
| Prognosis | |
| Cell Line, Tumor | |
| Glycosylation | |
| Female | |
| Platelet Endothelial Cell Adhesion Molecule-1 |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37683735 | AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. | J Hepatol | 2023 | https://conductscience.org/library/papers/37683735 | PubMed |
| 2 | 31905724 | Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. | J Clin Med | 2019 | https://conductscience.org/library/papers/31905724 | PubMed |
| 3 | 29706631 | O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29706631 | PubMed |
| 4 | 28430973 | Biological functions of fucose in mammals. | Glycobiology | 2017 | https://conductscience.org/library/papers/28430973 | PubMed |
| 5 | 22508695 | Anti-VEGF/VEGFR therapy for cancer: reassessing the target. | Cancer Res | 2012 | https://conductscience.org/library/papers/22508695 | PubMed |
| 6 | 35536554 | Comparison of Fucose-Specific Lectins to Improve Quantitative AFP-L3 Assay for Diagnosing Hepatocellular Carcinoma Using Mass Spectrometry. | J Proteome Res | 2022 | https://conductscience.org/library/papers/35536554 | PubMed |
| 7 | 31501519 | Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition. | Cell Res | 2019 | https://conductscience.org/library/papers/31501519 | PubMed |
| 8 | 18421054 | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18421054 | PubMed |
| 9 | 37353784 | m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37353784 | PubMed |
| 10 | 37071094 | Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37071094 | PubMed |
| 11 | 35739268 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. | Nat Med | 2022 | https://conductscience.org/library/papers/35739268 | PubMed |
| 12 | 19884117 | Fucosylated glycan inhibition of human hepatocellular carcinoma cell migration through binding to chemokine receptors. | Glycobiology | 2010 | https://conductscience.org/library/papers/19884117 | PubMed |
| 13 | 22427986 | Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. | PLoS One | 2012 | https://conductscience.org/library/papers/22427986 | PubMed |
| 14 | 7806582 | E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. | J Cell Biol | 1994 | https://conductscience.org/library/papers/7806582 | PubMed |
| 15 | 25972125 | Glycosyltransferases involved in the synthesis of MUC-associated metastasis-promoting selectin ligands. | Glycobiology | 2015 | https://conductscience.org/library/papers/25972125 | PubMed |
| 16 | 28391576 | Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. | Invest New Drugs | 2017 | https://conductscience.org/library/papers/28391576 | PubMed |
| 17 | 35020204 | Cancer statistics, 2022. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35020204 | PubMed |
| 18 | 37537172 | FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37537172 | PubMed |
| 19 | 33976130 | FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. | Nat Commun | 2021 | https://conductscience.org/library/papers/33976130 | PubMed |
| 20 | 38778217 | The OGT-c-Myc-PDK2 axis rewires the TCA cycle and promotes colorectal tumor growth. | Cell Death Differ | 2024 | https://conductscience.org/library/papers/38778217 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42558900 | Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558900 |
Source PubMed
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGO2 | 27161 | PubTator's text mining | https://conductscience.org/library/genes/27161 | NCBI Gene |
| HSBP1 | 3281 | PubTator's text mining | https://conductscience.org/library/genes/3281 | NCBI Gene |
| JUP | 3728 | PubTator's text mining | https://conductscience.org/library/genes/3728 | NCBI Gene |
| PECAM1 | 5175 | PubTator's text mining | https://conductscience.org/library/genes/5175 | NCBI Gene |
| POFUT2 | 23275 | PubTator's text mining | https://conductscience.org/library/genes/23275 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41583504
GET https://conductscience.org/api/papers/v1/41583504/references?page=2